These healthcare stocks offer high risk and high reward, but they aren't nearly as risky as penny stocks.
News & Analysis: Deciphera Pharmaceuticals, Inc.
The company announced a public stock offering as it prepares for a potential regulatory approval in 2020.
The solid end of the year performance meant shares nearly tripled in 2019.
They have what deep-pocketed pharmaceutical giants want.
DCPH earnings call for the period ending September 30, 2019.
Investors have run back to the stock after promising clinical results.
Good news on the trade front was instrumental in lifting many stocks on Tuesday.
Solid clinical results were just what the struggling pharma company needed.
Why Array BioPharma, Deciphera Pharmaceuticals, and Blueprint Medicines Are Up by Double Digits Today
Shares of all three cancer-focused companies shot higher after one of their peers got bought out for a sizable premium.
Can these red-hot drug stocks keep the momentum going?